FLAME 30
The Global Influenza Market
Report Highlights
The global influenza market reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.
Report Scope
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
Analyst Credentials
MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.
Report Highlights
The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 and 2018.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Comprehensive company profiles of major players.
Report Highlights
- Overall sales in the global influenza market were worth $5.3 billion in 2007, which declined to $3.7 billion in 2008, then increased to an estimated $5.5 billion in 2009. By 2014, it is projected to increase to $6.3 billion, for a 5-year CAGR of 2.7%.
- The largest segment of the market, vaccines, was valued at $2.8 billion in 2008; this is expected to increase to $3.2 billion in 2009, and is projected to reach $4.2 billion in 2014, for a 5-year CAGR of 5.6%.
- Sales in the therapeutics market amounted to $701 million in 2008, increased to an estimated $2.1 billion in 2009, and are expected to fall to $1.9 billion in 2014, for a 5-year CAGR of -2.4%.
Report Highlights
- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
- The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
- The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
- The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
